In view of the promising experimental results of combined anti-CD4+ anti-PD-1/PD-L1 mAbs therapy in our syngeneic model of disseminated NB and of previous reports of anti-CD4 mAbs for clinical use in humans42,43, this treatment may be potentially translated to NB patients. This evidence concerns the gene CD274 and neuroblastoma.